X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR)
Health Care · Biotechnology · US
$4.17
+3.22% today · +1.8% 1Y
X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $400.55M and employs 45 people.
Over the last twelve months the share price has gained 1.8%, trading between 2.80 and 4.83.
Tweenvest scores X4 Pharmaceuticals, Inc. across four factors: quality 28/100, value 66/100. Its strongest factor is value.
XFOR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $400.55M
- Revenue (TTM)
- $15.85M
- P/E
- —
- EPS
- -0.89
- Dividend yield
- —
- Beta (5Y)
- 0.39
- 52-week high
- $4.83
- 52-week low
- $2.80
- Avg volume (3M)
- —
- Shares outstanding
- 99.15M
- Employees
- 45
- Next earnings
- —
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
- ISIN
- US98420X2027
- Listed since
- Nov 16, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.